"Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceuticals Industries is pleased to announce ILUMYA (tildrakizumab injection), a treatment for adults living with moderate-to-severe plaque psoriasis, is now available in Canada.

We are excited to introduce this important biologic treatment to Canadians living with this common, inhibiting and often-overlooked disease. This launch is an important milestone for Sun Pharma, as we expand our dermatology portfolio into Canada," said Abhay Gandhi, CEO North America, Sun Pharma."

With five years of effective treatment of moderate-to-severe plaque psoriasis, ILUMYA demonstrates our commitment to providing innovative medicines to support patient lifestyle and physician choice.

"Plaque psoriasis is a chronic autoimmune disease that appears on the skin as red, raised areas of the skin covered with flaky white scales that can crack and bleed. It affects approximately 850,000 Canadians. Moderate-to-severe plaque psoriasis affects about 35% of patients. A key challenge is that many treatments stop working overtime and symptoms return. Durability of treatment in the long-term is an unmet need for many patients."

Moderate-to-severe plaque psoriasis can make it difficult to feel comfortable in your own skin and the search for an effective treatment can be as challenging as the disease itself," said Melinda Gooderham, a board-certified Dermatologist and Medical Director at the SKiN Centre for Dermatology in Peterborough, Ontario. "Our patients need options for an effective, durable and continuous treatment in Canada and ILUMYA will help meet that need."

Shares of the company declined Rs 17.70 or 2.14%, to settle  at  Rs 807.65.  The total volume of shares traded  was  64,340 at  the BSE (Thursday).